Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT100 in unexplained recurrent pregnancy loss
NCT02156063Phase 2Unknown
- Sponsor
- Nora Therapeutics, Inc.
- Start
- Jun 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NT100 in recurrent pregnancy loss (RPL), sponsored by Nora Therapeutics, Inc.. Status: unknown.
02
Drugs
NT100
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT02156063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156063.